Subscribe To

Price Alert Latest News Economic Calendar News

SIBN / SI-BONE, Inc. (SIBN) Q4 2022 Earnings Call Transcript

SI-BONE, Inc. (NASDAQ:SIBN ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Saqib Iqbal - Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord David Rescott - Truist Securities Craig Bijou - Bank of America Ross Osborn - Cantor Fitzgerald Dave Turkaly - JMP Securities Drew Ranieri - Morgan Stanley David Saxon - Needham & Company Operator Good afternoon, and welcome to SI-BONE's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Read More

Demo Live Account See Partner Details

Content Topics

Si

Bone

Inc

SIBN

2022

Earnings

Call

Transcript

Si bone

sibn

Stock

Posted: Feb 27 2023, 21:02

Author Name: Seeking Alpha

SIBN News

By GlobeNewsWire
November 1, 2023

SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023

SANTA CLARA, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal dis

By GlobeNewsWire
October 16, 2023

SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023

SANTA CLARA, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal dis

By Zacks Investment Research
October 9, 2023

Si-Bone (SIBN) Upgraded to Buy: Here's Why

Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

By Zacks Investment Research
September 8, 2023

Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?

Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

By Seeking Alpha
August 31, 2023

SI-BONE: Another Record Quarter, Reinvesting For Future Growth, Reiterate Buy

SI-BONE, Inc. presents compelling long-term value with robust growth in unit economics, high gross profits, and attractive valuation upside. Q2 FY'23

By GlobeNewsWire
August 29, 2023

SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023

SANTA CLARA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal dis

By Seeking Alpha
August 7, 2023

SI-BONE, Inc. (SIBN) Q2 2023 Earnings Call Transcript

SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director, FP&A and I

By GlobeNewsWire
July 19, 2023

SI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023

SANTA CLARA, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal dis

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.